Home » Stocks » OBLN

Obalon Therapeutics, Inc. (OBLN)

Stock Price: $3.52 USD -0.19 (-5.12%)
Updated Feb 26, 2021 1:56 PM EST - Market open
Market Cap 29.24M
Revenue (ttm) 2.31M
Net Income (ttm) -15.92M
Shares Out 7.73M
EPS (ttm) -2.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $3.52
Previous Close $3.71
Change ($) -0.19
Change (%) -5.12%
Day's Open 3.73
Day's Range 3.40 - 3.80
Day's Volume 176,719
52-Week Range 0.62 - 10.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

WILMINGTON, Del., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Obalon Therapeutics, Inc. (“Obalon”) (NASDAQ GS: OBLN) regarding possible breaches of...

PRNewsWire - 1 month ago

NEW YORK, Jan. 23, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities...

Business Wire - 1 month ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Obalon...

PRNewsWire - 1 month ago

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. ("O...

Benzinga - 1 month ago

Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and...

Other stocks mentioned: ADXN, GENE
Business Insider - 1 month ago

Shares of medical technology company Obalon Therapeutics exploded 568% to as high as $10.71 on Wednesday following a merger announcement with weight-loss company ReShape Lifesciences. Obalon's...

Benzinga - 1 month ago

Obalon Therapeutics Inc (NASDAQ: OBLN) shares are trading higher Wednesday after the company announced a merger agreement with ReShape Lifesciences. Obalon Therapeutics is a medical device com...

Market Watch - 1 month ago

Shares of Obalon Therapeutics Inc. blasted five-fold higher on massive volume in midday trading Wednesday, after the weight loss technologies company announced an agreement to merge with weigh...

InvestorPlace - 1 month ago

Obalon Therapeutics (OBLN) stock is skyrocketing on Wednesday after announcing merger plans with ReShape Lifesciences (RSLS). The post OBLN Stock: 12 Things to Know About the ReShape-Obalon Me...

InvestorPlace - 2 months ago

Obalon Therapeutics (OBLN) stock is skyrocketing higher Monday on heavy trading despite a lack of news from the medical device company. The post OBLN Stock: 11 Things to Know About Weight Loss...

Benzinga - 2 months ago

Obalon Therapeutics's (NASDAQ: OBLN) stock has been rising Monday, up 121.49% to a price of $1.9. The stock's volume is currently 17.38 million, which is roughly 1879.95% of its recent 30-day ...

Insider Monkey - 2 months ago

After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-f...

GlobeNewsWire - 6 months ago

SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastr...

GlobeNewsWire - 6 months ago

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas...

GlobeNewsWire - 8 months ago

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastr...

GlobeNewsWire - 9 months ago

SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the f...

GlobeNewsWire - 9 months ago

Obalon’s Executive Chairman, Andy Rasdal, will reassume CEO position Obalon’s Executive Chairman, Andy Rasdal, will reassume CEO position

GlobeNewsWire - 9 months ago

Obalon reported no device-related serious adverse events (0%) for first 141 patients completing therapy in post-approval study to FDA Obalon reported no device-related serious adverse events (...

GlobeNewsWire - 11 months ago

SAN DIEGO, March 25, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved...

GlobeNewsWire - 11 months ago

No patients or employees have been found to be symptomatic or positive for the virus, yet patient, employee, and public health remain Obalon’s highest priority No patients or employees have be...

Seeking Alpha - 11 months ago

Obalon Therapeutics, Inc. (OBLN) CEO Bill Plovanic on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Company continues to execute on its strategy to develop retail treatment sites focused exclusively on treatment with the Obalon Balloon System™ Company continues to execute on its strategy to ...

GlobeNewsWire - 1 year ago

SAN DIEGO, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved ...

Zacks Investment Research - 1 year ago

Is (OBLN) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 1 year ago

SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company with the first and only FDA-approved swallowable...

Seeking Alpha - 1 year ago

Obalon Therapeutics, Inc. (OBLN) Management on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 82.57% and -84.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the ...

Zacks Investment Research - 1 year ago

OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

Solidified leadership and strengthened financial position in place to leverage the Company’s safe and effective weight loss system in the retail medicine setting Solidified leadership and stre...

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gas...

Benzinga - 1 year ago

Shares of Obalon Therapeutics Inc (NASDAQ: OBLN), a developer of novel technologies for weight loss, were advancing strongly Thursday morning.

GlobeNewsWire - 1 year ago

Leading bariatric surgeon and authority in the field to oversee medical activities for the Obalon Center for Weight Loss located in San Diego, CA. Leading bariatric surgeon and authority in th...

Seeking Alpha - 1 year ago

Obalon Therapeutics Inc (OBLN) Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 7.41% and -78.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 1 year ago

Shares of micro-cap Obalon Therapeutics Inc (NASDAQ: OBLN) traded higher Tuesday after the company announced it has obtained two new U.S.

Benzinga - 1 year ago

Shares of micro-cap Obalon Therapeutics (traded higher after traders circulated the U.S. patent and trademark office abstract for its Intragastric device.

Benzinga - 1 year ago

Obalon Therapeutics Inc (NASDAQ: OBLN) shares have continued to be volatile — and that's no surprise, given that most low-float, low-volume stocks are susceptible to trader manipulation.

Benzinga - 1 year ago

Obalon Therapeutics Inc. shares rose 60 percent Wednesday morning, triggered by a Seeking Alpha post that said Johnson & Johnson could be making a bid for the company for $8 per share.

Zacks Investment Research - 1 year ago

In the latest trading session, OBALON THERPTCS (OBLN) closed at $0.68, marking a -0.37% move from the previous day.

Benzinga - 1 year ago

Medical technology company Obalon Therapeutics Inc. announced Thursday that it has entered into definitive agreements with investors for the purchase and sale of 5 million shares of common sto...

Zacks Investment Research - 1 year ago

OBALON THERPTCS (OBLN) closed the most recent trading day at $0.42, moving -1.96% from the previous trading session.

Zacks Investment Research - 1 year ago

OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About OBLN

Obalon Therapeutics, a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallow able capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the O... [Read more...]

Industry
Medical Devices
IPO Date
Oct 6, 2016
CEO
Andrew Rasdal
Employees
2
Stock Exchange
NASDAQ
Ticker Symbol
OBLN
Full Company Profile

Financial Performance

In 2019, OBLN's revenue was $3.28 million, a decrease of -63.95% compared to the previous year's $9.10 million. Losses were -$23.68 million, -36.65% less than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for OBLN stock is "Hold" and the 12-month stock price forecast is 6.15.

Price Target
$6.15
Analyst Consensus: Hold